Data may be delayed — last successful sync 2026-09-26 (18 days ago). Figures reflect the most recent completed ingest.
Company profile
Vext Science, Inc.
OTC: VEXTF · Healthcare · Drug Manufacturers - Specialty & Generic
#430 of 1,417 Healthcare companies by revenuetop-quartile growth
EA Score
63CFH 62DQ —GM 70SS 54
v0.1 · 45/100 weight · provisional
↑ revenue growth (YoY), workforce scale · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$50.4M
Rev growth YoY (TTM)
+14.2%
Net income (FY)
-$18.3M
Employees
173
as of 2026-09-18
Market cap
$46.4M
as of 2026-09-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$52.3M$52.3M2025
Net income-$18.3M-$18.3M2025
Operating income-$9.4M-$9.4M2025
Total assets$120.3M$120.3M2025
Liabilities$65.0M$65.0M2025
Equity$55.3M$55.3M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Vext Science, Inc.’s revenue?
Vext Science, Inc. booked $52.3M in FY2025 revenue, growing 45% year over year — faster than most Healthcare companies we track, at a -35.0% net margin.
Peers · Healthcare
Protalix BioTherapeutics, Inc.66BIRIDEX Corporation55C1CM Inc.71BOcular Therapeutix, Inc.62CNeptune Wellness Solutions Inc.——LENSAR Inc55CNeighbors
Maricopa →Key facts
CEOEric J. Offenberger
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersPhoenix, AZ
ExchangeOTC: VEXTF
Employees173
IPO date2019-05-28
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.